ClinicalTrials.gg
Active, not recruitingNCT06524232STUN IIUpdated Mar 25, 2026

The STop UNhealthy Substance Use Now Trial

An interventional study of Practice Facilitation (PF) and Learning Collaborative (LC) in Risky Health Behavior, Substance Use Disorders and Substance Abuse, sponsored by Ohio State University. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Ohio State University · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Health Risk Behaviors with a site in United States — 6 open to participants now, 9 under way, none of them phase 3. Health Risk Behaviors · United States.

Planned enrollment
12th of 24
144 · median 138
Started
2024
with 1 other
No phase
23 of 25
5 open now
Registered
21st of 25
by date
Lead sponsor
1 of 25
Ohio State University

Among the 25 studies in Health Risk Behaviors with a site in United States, this one is the 12th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2024, is one of 23 with no phase, and was the 21st registered.

Health Risk Behaviors

60 studies on the registry are indexed under Health Risk Behaviors; 16 are open to participants now.

Browse Health Risk Behaviors studies →

Open to participants now

6 of the 25 studies in Health Risk Behaviors with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Health Risk Behaviors studies recruiting now, 5 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Health Risk Behaviors with a site in United States, or all of them as a file.
02

Study summary

The STop UNhealthy (STUN) Substance Use Now Trial (STUN II) is a multisite trial aiming to evaluate the comparative effectiveness of the following strategies for improving the implementation of screening and interventions for substance use disorders in primary care: practice facilitation (PF), PF plus a learning collaborative (LC), PF plus performance incentives (PI), and PF+LC+PI. We plan to enroll 144 clinic staff participants from 48 primary care practices

Read the detailed description

The STop UNhealthy (STUN) Substance Use Now Trial (STUN II) is a multisite trial aiming to evaluate the comparative effectiveness of the following strategies for improving the implementation of screening and interventions for substance use disorders in primary care: practice facilitation (PF), PF plus a learning collaborative (LC), PF plus performance incentives (PI), and PF+LC+PI. We plan to enroll 144 clinic staff participants from 48 primary care practices

Specific aim 1 (primary aim) will compare the effect of learning collaborative (LC) participation, performance incentives (PI), or their combination, with practice facilitation (PF) only, on implementation of evidence-based screening for SUDs.

Specific aim 2 (secondary aim) will compare the effect of LC participation, PI, or their combination, with PF only, on implementation of evidence-based interventions for SUDs, including (a) brief counseling, (b) medications (e.g., buprenorphine, naltrexone) and adherence to them, and (c) referral to specialty care.

Specific aims 1 and 2 will produce fundamentally important evidence about the comparative effectiveness of PF, PF+LC, PF+PI, and PF+LC+PI strategies on uptake of evidence-based screening and interventions for SUD when delivered to primary care practices.

Specific aim 3 (exploratory aim) will use a longitudinal mixed-methods evaluation to assess the association between implementation effectiveness and putative moderators (e.g., organizational readiness for change) and mediators (e.g., implementation climate). Aim 3 will generate scientific knowledge about mechanisms of change (why and how the various strategies work) in primary care settings.

03

Conditions studied

  • Risky Health Behavior
  • Substance Use Disorders
  • Substance Abuse
  • Alcohol Use Disorder
  • Drinking, Alcohol
  • Substance Use
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinic staff members from primary care practices who provide care for adult patients and have a leadership role within the practice (e.g. lead physician, practice manager, lead medical assistant/nurse, clinical champion)

Exclusion criteria

Exclusion Criteria:

  • Clinic staff members who already have ongoing involvement in programs that would conflict with or preclude this study
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Active comparator
    Practice Facilitation Only

    Practice Facilitation: Practices will receive up to 2 hours of direct practice facilitation services per month for 12 months.

    Other: Practice Facilitation (PF)

  • Experimental
    Practice Facilitation + Learning Collaborative

    Practice Facilitation (PF): Practices will receive up to 2 hours of direct practice facilitation services per month for 12 months. Learning Collaborative (LC): Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A.

    Other: Practice Facilitation (PF) · Other: Learning Collaborative (LC)

  • Experimental
    Practice Facilitation + Performance Incentives

    Practice Facilitation: Practices will receive up to 2 hours of direct practice facilitation services per month for 12 months. Performance Incentives: Practices will receive a maximum total of $6,000 based on their performance during the 12-month implementation period. They will have the opportunity to receive up to $1,500 per quarter if they reach performance milestones for the quarter.

    Other: Practice Facilitation (PF) · Other: Performance Incentives (PI)

  • Experimental
    Practice Facilitation + Learning Collaborative + Performance Incentives

    Practice Facilitation: Practices will receive up to 2 hours of direct practice facilitation services per month for 12 months. Learning Collaborative (LC): Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A. Performance Incentives: Practices will receive a maximum total of $6,000 based on their performance during the 12-month implementation period. They will have the opportunity to receive up to $1,500 per quarter if they reach performance milestones for the quarter.

    Other: Practice Facilitation (PF) · Other: Learning Collaborative (LC) · Other: Performance Incentives (PI)

Interventions

  • OtherPractice Facilitation (PF)

    Practices will meet with practice facilitators monthly and apply tests of change using a Plan-Do-Study-Act approach, guided by the PF team. Facilitators will confirm that practices have established workflows for substance use disorder (SUD) screening and interventions and perform checks periodically to ensure progression. PF will entail: implementing protocols/algorithms for evidence-based screening and interventions, promoting decision support tools and templates to support practice workflow, optimizing electronic health record (EHR) use to pull clinical data monthly to guide the improvement process, developing patient registries (e.g., for those with SUD) to identify needed care and optimize delivery of evidence-based interventions, encouraging proactive, team-based care with assigned roles and responsibilities, and enhancing the understanding of evidence-based SUD interventions, including counseling and referral resources to ensure practices have appropriate intervention options.

  • OtherLearning Collaborative (LC)

    Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A. Participant-generated ideas for topics to be covered during virtual LC sessions will be encouraged. Some specific topics will include optimal SUD screening approaches; prescribing medications for opioid use disorder (OUD) in primary care; pragmatic issues around integrated SUD care within primary care such as compliance with state and federal requirements, note templates/visit frequency, and when/how to escalate care for patients with severe or worsening SUD; medications for alcohol use disorder (AUD); and motivational interviewing.

  • OtherPerformance Incentives (PI)

    We will work closely with key stakeholders and the Steering Committee to co-design the PI strategy, refining the specific performance metrics to ensure that they align with other ongoing efforts in our partnering organizations. We plan to base the incentive on achieving a threshold target for the percentage of eligible adult patients screened for SUD, or the percentage improvement in screening, for quarters 1 and 2. For quarters 3 and 4, after practices have had time to implement and improve their processes for screening for SUD, the incentives will evolve to become a composite of (1) patients screened for SUD (the same as used in quarters 1 and 2) and (2) achieving a threshold target for the percentage of persons with SUD who received evidence-based interventions.

06

What researchers measure

Primary outcomes

  1. Number of adults screened for substance use disorder

    Number of people aged 18 and older who are screened for substance use disorder using a validated screening tool

    Time frame: 12 months

  2. Percent of adults screened for substance use disorder

    Percent of people aged 18 and older who are screened for substance use disorder using a validated screening tool

    Time frame: 12 months

Secondary outcomes

  1. Number of adults with a positive screen for substance use disorder

    Of those aged 18 and older who were screened for substance use disorder, number who had a positive screening result

    Time frame: 12 months

  2. Number of adults with a positive screen for substance use disorder

    Of those aged 18 and older who were screened for substance use disorder, number who had a positive screening result

    Time frame: 24 months

  3. Percent of adults with a positive screen for substance use disorder

    Of those aged 18 and older who were screened for substance use disorder, percentage who had a positive screening result

    Time frame: 12 months

  4. Percent of adults with a positive screen for substance use disorder

    Of those aged 18 and older who were screened for substance use disorder, percentage who had a positive screening result

    Time frame: 24 months

  5. Number of adults who received any evidence-based intervention for substance use disorder

    Of those aged 18 or older who were identified as having substance use disorder and/or alcohol use disorder, number who received brief counseling, medication, or referral to specialty care

    Time frame: 12 months

  6. Number of adults who received any evidence-based intervention for substance use disorder

    Of those aged 18 or older who were identified as having substance use disorder and/or alcohol use disorder, number who received brief counseling, medication, or referral to specialty care

    Time frame: 24 months

  7. Percentage of adults who received any evidence-based intervention for substance use disorder

    Of those aged 18 or older who were identified as having substance use disorder and/or alcohol use disorder, percentage that received brief counseling, medication, or referral to specialty care

    Time frame: 24 months

  8. Percentage of adults who received any evidence-based intervention for substance use disorder

    Of those aged 18 or older who were identified as having substance use disorder and/or alcohol use disorder, percentage that received brief counseling, medication, or referral to specialty care

    Time frame: 12 months

  9. Number of adults who received brief counseling for substance use disorder

    Of people aged 18 or older who screened positive for substance use disorder and/or alcohol use disorder, number who received brief counseling

    Time frame: 12 months

  10. Number of adults who received brief counseling for substance use disorder

    Of people aged 18 or older who screened positive for substance use disorder and/or alcohol use disorder, number who received brief counseling

    Time frame: 24 months

  11. Percentage of adults who received brief counseling for substance use disorder

    Of people aged 18 or older who screened positive for substance use disorder and/or alcohol use disorder, percentage who received brief counseling

    Time frame: 24 months

  12. Percentage of adults who received brief counseling for substance use disorder

    Of people aged 18 or older who screened positive for substance use disorder and/or alcohol use disorder, percentage who received brief counseling

    Time frame: 12 months

  13. Number of adults who received medication for substance use disorder

    Of people aged 18 or older who screened positive for substance use disorder and/or alcohol use disorder, number who received medication

    Time frame: 12 months

  14. Number of adults who received medication for substance use disorder

    Of people aged 18 or older who screened positive for substance use disorder and/or alcohol use disorder, number who received medication

    Time frame: 24 months

  15. Percentage of adults who received medication for substance use disorder

    Of people aged 18 or older who screened positive for substance use disorder and/or alcohol use disorder, percentage who received medication

    Time frame: 24 months

  16. Percentage of adults who received medication for substance use disorder, including alcohol use disorder

    Of people aged 18 or older who screened positive for substance use disorder and/or alcohol use disorder, percentage who received medication

    Time frame: 12 months

  17. Number of adults who received medication for substance use disorder, including alcohol use disorder, and adhered to 6 months of treatment

    Of those aged 18 or older who received medication for substance use disorder and/or alcohol use disorder, number who adhered to treatment for 6 months

    Time frame: 12 months

  18. Number of adults who received medication for substance use disorder, including alcohol use disorder, and adhered to 6 months of treatment

    Of those aged 18 or older who received medication for substance use disorder and/or alcohol use disorder, number who adhered to treatment for 6 months

    Time frame: 24 months

  19. Percentage of adults who received medication for substance use disorder, including alcohol use disorder, and adhered to 6 months of treatment

    Of those aged 18 or older who received medication for substance use disorder and/or alcohol use disorder, percentage who adhered to treatment for 6 months

    Time frame: 24 months

  20. Percentage of adults who received medication for substance use disorder, including alcohol use disorder, and adhered to 6 months of treatment

    Of those aged 18 or older who received medication for substance use disorder and/or alcohol use disorder, percentage who adhered to treatment for 6 months

    Time frame: 12 months

  21. Number of adults referred to specialty care for substance use disorder and/or alcohol use disorder

    Of those aged 18 or older who were identified as having substance use disorder and/or alcohol use disorder, number who were referred to specialty care (psychiatry, 12-step programs, counseling, etc.)

    Time frame: 12 months

  22. Number of adults referred to specialty care for substance use disorder and/or alcohol use disorder

    Of those aged 18 or older who were identified as having substance use disorder and/or alcohol use disorder, number who were referred to specialty care (psychiatry, 12-step programs, counseling, etc.)

    Time frame: 24 months

  23. Percentage of adults referred to specialty care for substance use disorder and/or alcohol use disorder

    Of those aged 18 or older who were identified as having substance use disorder and/or alcohol use disorder, percentage who were referred to specialty care (psychiatry, 12-step programs, counseling, etc.)

    Time frame: 24 months

  24. Percentage of adults referred to specialty care for substance use disorder and/or alcohol use disorder

    Of those aged 18 or older who were identified as having substance use disorder and/or alcohol use disorder, percentage who were referred to specialty care (psychiatry, 12-step programs, counseling, etc.)

    Time frame: 12 months

  25. Number of adults with alcohol use disorder

    Of those aged 18 or older who were screened for substance use disorder, number who had alcohol use disorder

    Time frame: 12 months

  26. Number of adults with alcohol use disorder

    Of those aged 18 or older who were screened for substance use disorder, number who had alcohol use disorder

    Time frame: 24 months

  27. Percentage of adults with alcohol use disorder

    Of those aged 18 or older who were screened for substance use disorder, percentage who had alcohol use disorder

    Time frame: 24 months

  28. Percentage of adults with alcohol use disorder

    Of those aged 18 or older who were screened for substance use disorder, percentage who had alcohol use disorder

    Time frame: 12 months

  29. Number of adults who received any evidence-based intervention for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, number who received any evidence-based intervention (brief counseling, medication, referral to specialty care)

    Time frame: 12 months

  30. Number of adults who received any evidence-based intervention for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, number who received any evidence-based intervention (brief counseling, medication, referral to specialty care)

    Time frame: 24 months

  31. Percentage of adults who received any evidence-based intervention for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, percentage who received any evidence-based intervention (brief counseling, medication, referral to specialty care)

    Time frame: 24 months

  32. Percentage of adults who received any evidence-based intervention for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, percentage who received any evidence-based intervention (brief counseling, medication, referral to specialty care)

    Time frame: 12 months

  33. Number of adults who received brief counseling for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, number who received brief counseling

    Time frame: 12 months

  34. Number of adults who received brief counseling for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, number who received brief counseling

    Time frame: 24 months

  35. Percentage of adults who received brief counseling for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, percentage who received brief counseling

    Time frame: 24 months

  36. Percentage of adults who received brief counseling for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, percentage who received brief counseling

    Time frame: 12 months

  37. Number of adults who received medication for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, number who received medication

    Time frame: 12 months

  38. Number of adults who received medication for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, number who received medication

    Time frame: 24 months

  39. Percentage of adults who received medication for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, percentage who received medication

    Time frame: 24 months

  40. Percentage of adults who received medication for alcohol use disorder

    Of those aged 18 or older identified as having alcohol use disorder, percentage who received medication

    Time frame: 12 months

  41. Number of adults who received medication for alcohol use disorder and adhered to 6 months of treatment

    Of those aged 18 or older who received medication for alcohol use disorder, number who adhered to treatment for 6 months

    Time frame: 12 months

  42. Number of adults who received medication for alcohol use disorder and adhered to 6 months of treatment

    Of those aged 18 or older who received medication for alcohol use disorder, number who adhered to treatment for 6 months

    Time frame: 24 months

  43. Percentage of adults who received medication for alcohol use disorder and adhered to 6 months of treatment

    Of those aged 18 or older who received medication for alcohol use disorder, percentage who adhered to treatment for 6 months

    Time frame: 24 months

  44. Percentage of adults who received medication for alcohol use disorder and adhered to 6 months of treatment

    Of those aged 18 or older who received medication for alcohol use disorder, percentage who adhered to treatment for 6 months

    Time frame: 12 months

  45. Number of adults referred to specialty care for alcohol use disorder

    Of those aged 18 or older who were identified as having alcohol use disorder, number who were referred to specialty care (psychiatry, 12-step programs, counseling, etc.)

    Time frame: 12 months

  46. Number of adults referred to specialty care for alcohol use disorder

    Of those aged 18 or older who were identified as having alcohol use disorder, number who were referred to specialty care (psychiatry, 12-step programs, counseling, etc.)

    Time frame: 24 months

  47. Percentage of adults referred to specialty care for alcohol use disorder

    Of those aged 18 or older who were identified as having alcohol use disorder, percentage who were referred to specialty care (psychiatry, 12-step programs, counseling, etc.)

    Time frame: 24 months

  48. Percentage of adults referred to specialty care for alcohol use disorder

    Of those aged 18 or older who were identified as having alcohol use disorder, percentage who were referred to specialty care (psychiatry, 12-step programs, counseling, etc.)

    Time frame: 12 months

  49. Number of adults screened for substance use disorder

    Number of people aged 18 and older who are screened for substance use disorder using a validated screening tool

    Time frame: 24 months

  50. Percent of adults screened for substance use disorder

    Percent of people aged 18 and older who are screened for substance use disorder using a validated screening tool

    Time frame: 24 months

Other outcomes

  1. Association between implementation effectiveness and putative moderators and mediators

    Longitudinal mixed-methods evaluation (surveys, interviews) to describe the association between implementation effectiveness and putative moderators (e.g., organizational readiness for change) and mediators (e.g., implementation climate)

    Time frame: 12 months

  2. Association between implementation effectiveness and putative moderators and mediators

    Longitudinal mixed-methods evaluation (surveys, interviews) to describe the association between implementation effectiveness and putative moderators (e.g., organizational readiness for change) and mediators (e.g., implementation climate)

    Time frame: 24 months

07

Study locations

3 sites
08

References and documents

Publications

  • Jonas DE, Brill SB, Fried M, Brouwer L, Riley S, MacEwan SR, Hyer M, Palettas M, Hall OT, Vilensky M, Teater J, Carson WF 2nd, Wei L, Garner BR. The STop UNhealthy substance use now (STUN II) trial: protocol for a 48-site cluster randomized 2 x 2 factorial implementation trial to improve evidence-based screening and interventions for substance use disorder within primary care. Implement Sci. 2025 Sep 30;20(1):40. doi: 10.1186/s13012-025-01454-3. PubMed 41029867 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 36 non-industry interventional studies with no phase under Health Risk Behaviors, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 36 months is above that.

Counting every sponsor, half of 37 studies reached it within 18 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Jul 29, 2024
StartActual
Sep 16, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06524232
Collaborators
Ohio Association of Community Health Centers (OACHC), Bon Secours Mercy Health (BSMH), Agency for Healthcare Research and Quality (AHRQ)
Responsible party
Dan.Jonas (Director and Professor, Division of General Internal Medicine, Ohio State University) — Principal investigator
First posted
Jul 29, 2024
Start date
Sep 16, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Mar 25, 2026

Study contacts

Daniel E Jonas, MD, MPH
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion